Cell‑based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report

  • Authors:
    • Ranganathan Chidambaram
    • Hiroshi Terunuma
    • Madasamy Balamurugan
    • Vidyasagar Devaprasad Dedeepiya
    • Premkumar Sumana
    • Rajappa Senthilkumar
    • Mathaiyan Rajmohan
    • Ramalingam Karthick
    • Senthilkumar Preethy
    • Samuel J.K. Abraham
  • View Affiliations

  • Published online on: July 19, 2017     https://doi.org/10.3892/mco.2017.1333
  • Pages: 493-497
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer stem cells in breast cancer migrating to the bone marrow may cause future metastasis, particularly during periods of decreased immunity. Natural killer (NK) cells have a role in immune surveillance and are able to target cancer stem cells. The present study reported a case in which NK cell‑based autologous immune enhancement therapy was used combined with conventional treatments in a patient with stage IIIA breast cancer, yielding >28 months of disease‑free survival. However, there was a gradual decline in the in vitro expansion of NK cells with subsequent chemotherapeutic treatments. As this NK cell decline following chemotherapy may contribute to cancer cell immune evasion and future metastasis; modifying current cancer therapies in order to avoid potentially compromising the immune system may lead to improved treatment outcomes.

References

1 

World Cancer Report. International Agency for Research on Cancer. 2008, Available at. simplehttp://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.phpApril 29–2016

2 

Dittmer J and Rody A: Cancer stem cells in breast cancer. Histol Histopathol. 28:827–838. 2013.PubMed/NCBI

3 

Corcoran KE, Trzaska KA, Fernandes H, Bryan M, Taborga M, Srinivas V, Packman K, Patel PS and Rameshwar P: Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One. 3:e25632008. View Article : Google Scholar : PubMed/NCBI

4 

Terunuma H, Deng X, Dewan Z, Fujimoto S and Yamamoto N: Potential role of NK cells in the induction of immune responses: Implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol. 27:93–110. 2008. View Article : Google Scholar : PubMed/NCBI

5 

Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, Alva JA, Walter G, Head C, Ishikawa TO, et al: Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One. 5:e115902010. View Article : Google Scholar : PubMed/NCBI

6 

Yin T, Wang G, He S, Liu Q, Sun J and Wang Y: Human cancer cells with stem cell-like phenotype exhibit enhanced sensitivity to the cytotoxicity of IL-2 and IL-15 activated natural killer cells. Cell Immunol. 300:41–45. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet. 356:802–807. 2000. View Article : Google Scholar : PubMed/NCBI

8 

Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T and Matsumoto Y: Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: A randomized trial. Clin Cancer Res. 8:1767–1771. 2002.PubMed/NCBI

9 

Egawa K: Immuno-cell therapy of cancer in Japan. Anticancer Res. 24:3321–3326. 2004.PubMed/NCBI

10 

Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, Yamamoto N and Toi M: Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer. 18:64–67. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Domschke C, Ge Y, Bernhardt I, Schott S, Keim S, Juenger S, Bucur M, Mayer L, Blumenstein M, Rom J, et al: Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: Follow-up analysis of a clinical pilot trial. Cancer Immunol Immunother. 62:1053–1060. 2013. View Article : Google Scholar : PubMed/NCBI

12 

Kotsakis A, Sarra E, Peraki M, Koukourakis M, Apostolaki S, Souglakos J, Mavromanomakis E, Vlachonikolis J and Georgoulias V: Docetaxel-induced lymphopenia in patients with solid tumors: A prospective phenotypic analysis. Cancer. 89:1380–1386. 2000. View Article : Google Scholar : PubMed/NCBI

13 

Bloom HJ and Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 11:359–377. 1957. View Article : Google Scholar : PubMed/NCBI

14 

Sobin LH, Gospodarowicz MK and Wittekind CH: TNM Classification of Malignant Tumors. 7th edition. Wiley-Blackwell; Oxford: 2009

15 

Premkumar S, Dedeepiya VD, Terunuma H, Senthilkumar R, Srinivasan T, Reena HC, Preethy S and Abraham SJ: Cell based autologous immune enhancement therapy (AIET) after radiotherapy in a locally advanced carcinoma of the cervix. Case Rep Oncol Med. 2013:9030942013.PubMed/NCBI

16 

Manjunath SR, Ramanan G, Dedeepiya VD, Terunuma H, Deng X, Baskar S, Senthilkumar R, Thamaraikannan P, Srinivasan T, Preethy S and Abraham SJ: Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: A case report. Case Rep Oncol. 5:114–118. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Dedeepiya V, Terunuma H, Deng X, Baskar S, Manjunath S, Senthilkumar R, Murugan P, Thamaraikannan P, Srinivasan T, Preethy S and Abraham SJ: A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours. Oncol Lett. 3:435–440. 2012.PubMed/NCBI

18 

Gogia A, Raina V, Deo SV, Shukla NK, Mohanti BK and Sharma DN: Inflammatory breast cancer: A single centre analysis. Asian Pac J Cancer Prev. 15:3207–3210. 2014. View Article : Google Scholar : PubMed/NCBI

19 

Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L, Ramacher M, Kato M, Schadendorf D, Baniyash M and Umansky V: Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol. 133:1610–1619. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P and Boulamatsis D: Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 87:21–27. 2002. View Article : Google Scholar : PubMed/NCBI

21 

Tai LH, de Souza CT, Bélanger S, Ly L, Alkayyal AA, Zhang J, Rintoul JL, Ananth AA, Lam T, Breitbach CJ, et al: Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res. 73:97–107. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Fridman WH, Remark R, Goc J, Giraldo NA, Becht E, Hammond SA, Damotte D, Dieu-Nosjean MC and Sautès-Fridman C: The immune microenvironment: A major player I human cancers. Int Arch Allergy Immunol. 164:13–26. 2014. View Article : Google Scholar : PubMed/NCBI

23 

Sznurkowski JJ, Zawrocki A and Biernat W: Subtypes of cytotoxic lymphocytes and natural killer cells infiltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma. Cancer Immunol Immunother. 63:297–303. 2014. View Article : Google Scholar : PubMed/NCBI

24 

Shafer D, Smith MR, Borghaei H, Millenson MM, Li T, Litwin S, Anad R and Al-Saleem T: Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. Leuk Res. 37:1213–1235. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Hanna N and Fidler IJ: Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst. 65:801–809. 1980. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2017
Volume 7 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chidambaram, R., Terunuma, H., Balamurugan, M., Dedeepiya, V.D., Sumana, P., Senthilkumar, R. ... Abraham, S.J. (2017). Cell‑based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report. Molecular and Clinical Oncology, 7, 493-497. https://doi.org/10.3892/mco.2017.1333
MLA
Chidambaram, R., Terunuma, H., Balamurugan, M., Dedeepiya, V. D., Sumana, P., Senthilkumar, R., Rajmohan, M., Karthick, R., Preethy, S., Abraham, S. J."Cell‑based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report". Molecular and Clinical Oncology 7.3 (2017): 493-497.
Chicago
Chidambaram, R., Terunuma, H., Balamurugan, M., Dedeepiya, V. D., Sumana, P., Senthilkumar, R., Rajmohan, M., Karthick, R., Preethy, S., Abraham, S. J."Cell‑based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report". Molecular and Clinical Oncology 7, no. 3 (2017): 493-497. https://doi.org/10.3892/mco.2017.1333